Clinical

Dataset Information

0

Phase I Platinum Based Chemotherapy Plus Indomethacin


ABSTRACT: Mesenchymal stem cells (MSCs) are present in the circulation of cancer patients, and are recruited to the stroma of both the primary tumor and metastasis. Recent preclinical research has shown that in response to platinum-based chemotherapy, MSCs secrete two specific platinum-induced fatty acids (PIFAs) which induce resistance to a broad spectrum of chemotherapies. The secreted PIFAs are the fatty acid oxo-heptadecatetraenoic acid (KHT) and the omega-3 fatty acid hexadecatetraenoic acid (16:4). These PIFAs are produced via the COX-1 pathway. COX inhibitors, including indomethacin. This phase 1 study explores the safety of combining indomethacin with platinum containing chemotherapy.

DISEASE(S): Esophageal Neoplasms,Colorectal Neoplasms,Ovarian Neoplasms,Neoplasms

PROVIDER: 2134582 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2020-03-30 | GSE119080 | GEO
2024-02-17 | GSE231560 | GEO
2022-01-04 | GSE163152 | GEO
2023-09-26 | GSE243704 | GEO
2017-03-08 | GSE95777 | GEO
| PRJNA16295 | ENA
2021-02-27 | GSE160086 | GEO
2012-02-21 | E-GEOD-32273 | biostudies-arrayexpress
2016-05-01 | GSE80081 | GEO
2016-05-01 | GSE80080 | GEO